Protective effect of oral anticoagulant drugs in atrial fibrillation patients admitted for COVID-19: Results from the CORIST study
- PMID: 34020162
- PMCID: PMC8123369
- DOI: 10.1016/j.thromres.2021.05.006
Protective effect of oral anticoagulant drugs in atrial fibrillation patients admitted for COVID-19: Results from the CORIST study
Conflict of interest statement
Dr. Ageno reports grants and personal fees from Bayer, personal fees from BMS/Pfizer, personal fees from Daiichi Sankyo, personal fees from Aspen, personal fees from Portola, personal fees from Janssen, personal fees from Sanofi, outside the submitted work.
Comment on
-
Reduction in all-cause mortality in COVID-19 patients on chronic oral anticoagulation: A population-based propensity score matched study.Int J Cardiol. 2021 Apr 15;329:266-269. doi: 10.1016/j.ijcard.2020.12.024. Epub 2020 Dec 11. Int J Cardiol. 2021. PMID: 33309764 Free PMC article.
References
-
- Spyropoulos A.C., Levy J.H., Ageno W., Connors J.M., Hunt B.J., Iba T., Levi M., Samama C.M., Thachil J., Giannis D., Douketis J.D. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. 2020;18:1859–1865. - PMC - PubMed
-
- Docherty A.B., Harrison E.M., Green C.A., Hardwick H.E., Pius R., Norman L., Holden K.A., Read J.M., Dondelinger F., Carson G., Merson L., Lee J., Plotkin D., Sigfrid L., Halpin S., Jackson C., Gamble C., Horby P.W., Nguyen-Van-Tam J.S., Ho A., Russell C.D., Dunning J., Openshaw P.J., Baillie J.K., Semple M.G., ISARIC4C investigators Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
